Published 14 days ago

Monoclonal antibody Prasinezumab shows promise in slowing rapid Parkinson's progression

Summary by News Medical

A recent study in Nature Medicine evaluated the efficacy of prasinezumab, a monoclonal antibody, in slowing the progression of motor symptoms in Parkinson’s disease patients with rapidly progressing forms, using phase II clinical trial data.

0 Articles

All

Left

Center

Right

News Medical

Monoclonal antibody Prasinezumab shows promise in slowing rapid Parkinson's progression

14 days ago·United States

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Ground News Article Assistant

Not enough coverage to generate an Article Assistant.

Coverage Details

Total News Sources0

Leaning Left0Leaning Right0Center1Last Updated14 days agoBias Distribution

100% Center

Bias Distribution

100% of the sources are Center

100% Center

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

Monoclonal antibody Prasinezumab shows promise in slowing rapid Parkinson's progression

0 Articles

0 Articles

Monoclonal antibody Prasinezumab shows promise in slowing rapid Parkinson's progression

Monoclonal antibody Prasinezumab shows promise in slowing rapid Parkinson's progression

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics